Breakthrough Pneumococcal Bacteremia in Patients Being Treated with Azithromycin and Clarithromycin
| Autor: | Peter H. Gilligan, Myron S. Cohen, David J. Weber, Meera Kelley |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Male
Microbiology (medical) medicine.medical_specialty medicine.drug_class Bacteremia Azithromycin medicine.disease_cause Pneumococcal Infections Macrolide Antibiotics Clarithromycin Internal medicine Streptococcus pneumoniae medicine Humans Treatment Failure Intensive care medicine Aged Antibacterial agent business.industry Drug Resistance Microbial Middle Aged medicine.disease Anti-Bacterial Agents Pneumococcal infections Infectious Diseases Child Preschool Female business Empiric therapy medicine.drug |
| Zdroj: | Clinical Infectious Diseases. 31:1008-1011 |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1086/318157 |
| Popis: | Streptococcus pneumoniae strains have exhibited decreasing susceptibility to penicillins and macrolides during the past several years. We reviewed the medical charts of all patients with pneumococcal bacteremia who were admitted to a university hospital over a period of 1 year, to identify failures of outpatient therapy. Of 41 patients admitted with pneumococcal bacteremia, 4 had previously taken either azithromycin or clarithromycin for 3-5 days. All 4 had pneumococcal strains that exhibited low-level resistance to macrolide antibiotics. Among pneumococci, low-level resistance to macrolides can lead to clinical failure, and resistance to macrolides should be considered during the selection of empiric therapy for patients with presumed pneumococcal infections. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|